A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Public ClinicalTrials.gov record NCT03634540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.
Study identification
- NCT ID
- NCT03634540
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 118 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2018 (Actual)
- Primary completion
- Feb 26, 2027 (Estimated)
- Completion
- Feb 26, 2027 (Estimated)
- Last update posted
- Dec 20, 2024
2018 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Comprehensive Cancer Center ( Site 0060) | Los Angeles | California | 90033 | — |
| Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0003) | Los Angeles | California | 90048 | — |
| Sylvester Comprehensive Cancer Center ( Site 0023) | Miami | Florida | 33136 | — |
| Dana Farber Cancer Center ( Site 0006) | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute ( Site 0033) | Detroit | Michigan | 48201 | — |
| Tennessee Oncology, PLLC ( Site 0024) | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology, PLLC ( Site 0001) | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 0010) | Dallas | Texas | 75246 | — |
| Swedish Cancer Institute ( Site 0018) | Seattle | Washington | 98104 | — |
| Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0035) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03634540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 20, 2024 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03634540 live on ClinicalTrials.gov.